Mark McHale
Chief Scientific Officer, Oak Hill Bio Limited
I am a founder of Oak Hill Bio, an innovative biotechnology company dedicated to rare diseases in neonatology and autoimmunity. Previously I was founder and Head of R&D and Chief Development Officer at ASLAN Pharmaceuticals where I was responsible for in-licensing several drugs targeting oncology and allergic inflammation. I licensed ASLAN004 from CSL Behring, a first in-class therapeutic monoclonal antibody targeting the IL-13Ra1 and progressed this drug to a successful proof of concept in severe atopic dermatitis. I have been in R&D for over 30 years in big pharma and biotech focussing on inflammation and oncology.
